Business Context and Reporting Period
Galectin Therapeutics Inc. is a development-stage biotechnology company developing galectin-targeting therapies for cancer and fibrotic disease. The filing reports unaudited results for the three months ended March 31, 2012, compared with the same period in 2011. The company had no commercial revenue and had accumulated development-stage losses since inception in July 2000.
Lead programs included GM-CT-01 for cancer, in a Phase I/II melanoma combination trial, and GR-MD-02 for liver fibrosis and fatty liver disease, which remained in preclinical studies.
Key Financial Metrics
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | — |
| Research and development expense | $0.901 million | $0.744 million | Up 21% |
| General and administrative expense | $1.052 million | $1.269 million | Down 17% |
| Total operating expenses | $1.953 million | $2.013 million | Down 3% |
| Operating loss | $1.953 million | $2.013 million | Improved $0.060 million |
| Net loss | $1.950 million | $2.392 million | Improved $0.442 million |
| Net loss applicable to common stockholders | $2.204 million | $2.722 million | Improved $0.518 million |
| Basic and diluted loss per share | $0.17 | $0.24 | Improved $0.07 |
| Net cash used in operating activities | $1.486 million | $1.367 million | Use increased $0.119 million |
| Cash and cash equivalents at period-end | $15.314 million | $6.948 million | Up $8.366 million |
Cash increased primarily from the March 2012 public offering. The company reported no cash used in investing activities during the quarter and $10.403 million of net cash provided by financing activities. Total assets were $15.538 million and total liabilities were $2.135 million at March 31, 2012. The company reported no conventional long-term debt, but had redeemable convertible preferred stock with stated redemption values totaling approximately $8.333 million.
Contractual operating lease payments totaled $0.131 million, all due within one year. Accrued expenses included a $1.0 million deferred severance obligation.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased $0.157 million, primarily because of increased preclinical fibrosis activity, clinical-program work, and drug manufacturing costs.
- General and administrative expense decreased $0.217 million, reflecting lower payroll, business-development, and legal and accounting costs, partially offset by higher stock-based compensation.
- Net loss narrowed despite higher research spending, partly because Q1 2011 included a $0.384 million expense from a change in the fair value of warrant liabilities; the company had no warrant liabilities during Q1 2012.
- On March 28, 2012, the company issued 2,666,722 common shares and warrants to purchase 1,333,361 shares for gross proceeds of $12.0 million and net cash proceeds of $10.403 million.
- The company completed a one-for-six reverse stock split effective March 23, 2012 and began trading on the NASDAQ Capital Market under the symbol GALT.
- Common shares outstanding increased from 12,919,538 at December 31, 2011 to 15,670,612 at March 31, 2012; 15,721,003 shares were outstanding as of May 10, 2012.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management stated that March 31, 2012 unrestricted cash was sufficient to fund operations through 2013, but the company was actively seeking additional capital.
- If additional financing is not obtained or products do not reach the market before the end of 2013, management stated that the company may need to cease operations or seek bankruptcy protection.
- Management expected the first stage of the Belgian GM-CT-01 melanoma trial to be completed within approximately one year after first-patient enrollment. Stage 2 was estimated to require approximately $1 million of company funding.
- The company planned to seek an FDA IND for GR-MD-02 by the end of 2012, begin a Phase I NASH study in early 2013, and initiate a Phase II study by the end of 2013, with preliminary top-line results expected by the end of 2014. These are plans, not assured outcomes.
- The $0.2 million payment received from PROCAPS remained recorded as deferred revenue because contractual deliverables had not been completed. Colombian regulatory approval and related commercial revenue were uncertain.
- Former CEO David Platt initiated arbitration on May 2, 2012 seeking payment of the accrued $1.0 million severance obligation. The company disputed the claim and intended to contest it.
- The principal risks were continued operating losses, dependence on external financing, clinical and preclinical development failure, regulatory delays or rejection, intellectual-property risks, competition, and potential inability to commercialize products.
- Stock options and warrants represented substantial potential dilution: 7,424,241 warrants, 2,997,468 options, and 2,627,110 shares issuable upon preferred-stock conversion were excluded from diluted loss per share because they were anti-dilutive.
Most Important Facts for Investors to Verify
- Whether cash burn and planned clinical-development spending remain consistent with management’s stated funding horizon through 2013.
- Whether the company can obtain additional financing without substantial dilution or unfavorable terms.
- Enrollment, safety, efficacy, and funding status of the GM-CT-01 melanoma trial.
- Progress toward the GR-MD-02 IND and planned NASH clinical trials.
- Status and resolution of the $1.0 million severance arbitration and any effect on liquidity.
- Any regulatory approval or commercial progress under the PROCAPS agreement and whether the $0.2 million deferred revenue becomes recognizable.
- The dilutive impact of outstanding warrants, options, and convertible preferred stock.